EP1236473A3 - Systeme de livraison d'un polynucleotide a assemblage autonome - Google Patents

Systeme de livraison d'un polynucleotide a assemblage autonome Download PDF

Info

Publication number
EP1236473A3
EP1236473A3 EP02001408A EP02001408A EP1236473A3 EP 1236473 A3 EP1236473 A3 EP 1236473A3 EP 02001408 A EP02001408 A EP 02001408A EP 02001408 A EP02001408 A EP 02001408A EP 1236473 A3 EP1236473 A3 EP 1236473A3
Authority
EP
European Patent Office
Prior art keywords
components
self
delivery system
polynucleotide
polynucleotide delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02001408A
Other languages
German (de)
English (en)
Other versions
EP1236473A2 (fr
Inventor
Francis C. Szoka, Jr.
Jean Aventis Pasteur SA Haensler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California, San Diego
Original Assignee
University of California
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27127858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1236473(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, University of California Berkeley, University of California, San Diego filed Critical University of California
Publication of EP1236473A2 publication Critical patent/EP1236473A2/fr
Publication of EP1236473A3 publication Critical patent/EP1236473A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2261/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G2261/30—Monomer units or repeat units incorporating structural elements in the main chain
    • C08G2261/31—Monomer units or repeat units incorporating structural elements in the main chain incorporating aromatic structural elements in the main chain
    • C08G2261/312—Non-condensed aromatic systems, e.g. benzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP02001408A 1992-04-03 1993-04-05 Systeme de livraison d'un polynucleotide a assemblage autonome Withdrawn EP1236473A3 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86487692A 1992-04-03 1992-04-03
US864876 1992-04-03
US91366992A 1992-07-14 1992-07-14
US913669 1992-07-14
EP93909508A EP0636028B1 (fr) 1992-04-03 1993-04-05 Systeme de livraison d'un polynucleotide a assemblage autonome comprenant un peptide cationique amphiphatique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP93909508A Division EP0636028B1 (fr) 1992-04-03 1993-04-05 Systeme de livraison d'un polynucleotide a assemblage autonome comprenant un peptide cationique amphiphatique

Publications (2)

Publication Number Publication Date
EP1236473A2 EP1236473A2 (fr) 2002-09-04
EP1236473A3 true EP1236473A3 (fr) 2003-01-15

Family

ID=27127858

Family Applications (2)

Application Number Title Priority Date Filing Date
EP93909508A Expired - Lifetime EP0636028B1 (fr) 1992-04-03 1993-04-05 Systeme de livraison d'un polynucleotide a assemblage autonome comprenant un peptide cationique amphiphatique
EP02001408A Withdrawn EP1236473A3 (fr) 1992-04-03 1993-04-05 Systeme de livraison d'un polynucleotide a assemblage autonome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP93909508A Expired - Lifetime EP0636028B1 (fr) 1992-04-03 1993-04-05 Systeme de livraison d'un polynucleotide a assemblage autonome comprenant un peptide cationique amphiphatique

Country Status (11)

Country Link
US (3) US6300317B1 (fr)
EP (2) EP0636028B1 (fr)
JP (4) JP4074658B2 (fr)
AT (1) ATE260679T1 (fr)
AU (1) AU682308C (fr)
CA (1) CA2133323C (fr)
DE (1) DE69333434T2 (fr)
DK (1) DK0636028T3 (fr)
ES (1) ES2221920T3 (fr)
PT (1) PT636028E (fr)
WO (1) WO1993019768A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655468B2 (en) 1995-01-23 2010-02-02 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
CA2163364C (fr) * 1993-07-14 2009-10-27 Francis C. Szoka, Jr. Systeme d'administration auto-elabore de polynucleotides, renfermant des polycations dendrimeres
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
DE4418965A1 (de) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
WO1995034647A1 (fr) * 1994-06-13 1995-12-21 Vanderbilt University Compositions et procedes d'amelioration de l'apport d'acides nucleiques a des cellules
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
CA2216844A1 (fr) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Derives d'amidite et derives d'oligonucleotides
ES2336857T3 (es) * 1995-05-04 2010-04-16 Gilead Sciences, Inc. Complejos de ligandos de acido nucleico.
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
WO1996040961A1 (fr) * 1995-06-07 1996-12-19 Life Technologies, Inc. Transfection par lipides cationiques amelioree par des peptides
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
WO1996041606A2 (fr) * 1995-06-08 1996-12-27 Therexsys Limited Compositions pharmaceutiques ameliorees utilisees pour la therapie genique
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6444806B1 (en) * 1996-04-30 2002-09-03 Hisamitsu Pharmaceutical Co., Inc. Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
CA2271325A1 (fr) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation de formulations stables de complexes de type lipide-acide nucleique pour une administration efficace in vivo
IL129922A0 (en) 1996-11-15 2000-02-29 Canji Inc Tissue specific expression of retinoblastoma protein
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
CA2297375A1 (fr) 1997-07-24 1999-02-04 Valentis, Inc. Systeme d'expression de ghrh et procedes d'utilisation
AUPP373698A0 (en) * 1998-05-27 1998-06-18 Commonwealth Scientific And Industrial Research Organisation Molecular coatings
US6300319B1 (en) * 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
WO2000009086A2 (fr) 1998-08-14 2000-02-24 Valentis, Inc. Formulation protegee, dans un seul flacon, pour molecules d'acide nucleique, ses procedes de fabrication par melangeage en ligne, produits et procedes associes
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
FR2785293B1 (fr) 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
CA2350882C (fr) 1998-11-12 2011-02-22 Life Technologies Corporation Reactifs de transfection
US6277489B1 (en) * 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
AU764660B2 (en) * 1999-01-08 2003-08-28 Lonza Cologne Ag Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
EP1046394A3 (fr) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Nouvelles compositions utilisables pour la délivrance de composés dans une cellule
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8541548B2 (en) * 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
WO2001023537A1 (fr) * 1999-09-24 2001-04-05 Cyto Pulse Sciences, Inc. Procede servant a promouvoir l'administration assistee par champ electrique de materiaux biologiques dans des cellules
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2388301C (fr) 1999-10-22 2011-01-04 Aventis Pasteur Limited Molecule gp100 modifiee et ses applications
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE10016881B4 (de) * 2000-04-05 2006-06-01 Qiagen Gmbh Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
EP1792995A3 (fr) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Antigènes de chlamydia et fragments d'adn correspondants, et utilisations de ceux-ci
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
FR2825364A1 (fr) * 2001-05-29 2002-12-06 Genethon Iii Vecteur peptiidique pour le transfert d'acides nucleiques dans des cellules eucaryotes
AU2002348417B9 (en) 2001-10-26 2010-02-04 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
AR037778A1 (es) 2001-12-11 2004-12-01 Advisys Inc Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
EP1356820A1 (fr) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccin ADN combiné avec un inducteur de l'apoptose de cellules tumorales
GB0228525D0 (en) * 2002-12-06 2003-01-15 Univ Cambridge Tech Polymers and their use
US7695752B2 (en) 2003-01-24 2010-04-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
AU2003256803B2 (en) * 2003-01-24 2009-09-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
WO2004081040A2 (fr) 2003-03-12 2004-09-23 Advisys, Inc. Suplementation d'igf-i avec mediation par plasmide pour applications therapeutiques
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
WO2006030788A1 (fr) * 2004-09-14 2006-03-23 Shinichiro Isobe Intercaleur et procede de detection de gene utilisant ledit intercaleur
WO2006118547A1 (fr) 2005-04-29 2006-11-09 Agency For Science, Technology And Research Polymeres hyperramifies et leurs applications
WO2007031098A1 (fr) * 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7957466B2 (en) * 2005-09-16 2011-06-07 Sony Corporation Adaptive area of influence filter for moving object boundaries
EP2564864B8 (fr) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University Méthodes associées au FGF2 pour diagnostiquer et traiter une dépression
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US8017109B2 (en) * 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
CA2662520A1 (fr) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Conjugues polymeres contenant des fragments charges positivement
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009143864A1 (fr) * 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
EP2411519B1 (fr) 2009-03-27 2015-07-22 Institut National de la Santé et de la Recherche Médicale Acide nucléique antisens de la kanamycine pour le traitement contre le cancer
GB0918679D0 (en) 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
GB0918782D0 (en) 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
AU2010346373A1 (en) 2010-02-19 2012-08-02 Universite De Liege A polynucleotide for use in treatment of influenza A virus induced diseases, encoding modified Mx protein, said modified Mx protein, and a transgenic animal expressing gene encoding modified Mx protein
PH12012501596A1 (en) * 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
GB201004475D0 (en) 2010-03-17 2010-05-05 Isis Innovation Gene silencing
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
WO2012013249A1 (fr) 2010-07-30 2012-02-02 Université de Liège Protéine 1 de la matrice dentinaire (dmp1) pour l'utilisation dans des compositions pharmaceutiques
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9849087B2 (en) * 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
CN104271772A (zh) 2012-03-29 2015-01-07 科罗拉多州立大学董事会,公司实体 点击核酸
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
JP2016528176A (ja) 2013-06-06 2016-09-15 ジェイ ローランズ、デビッド シングルドメイン抗体ディスプレイ
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
EP3430060A4 (fr) * 2016-03-15 2019-11-27 Société De Commercialisation Des Produits De La Recherche Appliquée - SOCPRA Sciences Santé Et Humaines S.E.C. Conjugués favorisant l'accumulation cellulaire totale
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
WO2019112965A1 (fr) * 2017-12-04 2019-06-13 The Regents Of The University Of California Compositions et procédés pour l'apport de macromolécules
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
WO2020097261A1 (fr) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nouvelles compositions et nouveaux procédés de traitement de globinopathies
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
CA3195019A1 (fr) 2020-10-06 2022-04-14 Maria Fardis Traitement de patients souffrant de cpnpc avec des therapies de lymphocytes infiltrant les tumeurs
WO2022076606A1 (fr) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
IL303671A (en) 2020-12-18 2023-08-01 Defence Therapeutics Inc Antigens that have been covalently modified to improve immune response and/or stability
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024517460A (ja) 2021-05-06 2024-04-22 ディフェンス・セラピューティクス・インコーポレーテッド ステロイド酸ベースの免疫原エンハンサー
IL308337A (en) 2021-05-13 2024-01-01 Us Health Preparations and methods for the treatment of sickle cell disease
CA3226942A1 (fr) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Traitement de patients atteints d'un cancer avec des therapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de kras
US20230321268A1 (en) 2021-10-18 2023-10-12 Defence Therapeutics Inc. Conjugates enhancing total cellular accumulation
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20260139028A1 (en) 2021-11-02 2026-05-21 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3238259A1 (fr) 2021-11-16 2023-05-25 Defence Therapeutics Inc. Composes cytotoxiques a base d'acide steroide-peptide
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
EP4507704A1 (fr) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti
US12233130B2 (en) 2022-12-22 2025-02-25 Defence Therapeutics Inc. Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity
WO2024200831A1 (fr) 2023-03-30 2024-10-03 Vivadju Acide nucléique pvax14 en combinaison avec l'acide all-trans rétinoïque (atra) et un inhibiteur de point de contrôle pour le traitement du cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650909A (en) * 1984-11-28 1987-03-17 Yoakum George H Polyethylene glycol (PEG) reagent
EP0388758A1 (fr) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Conjugé protéine-polycation
EP0394111A1 (fr) * 1989-04-17 1990-10-24 Centre National De La Recherche Scientifique (Cnrs) Nouvelles lipopolyamines, leur préparation et leur emploi
WO1991004753A1 (fr) * 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
WO1991015501A1 (fr) * 1990-04-04 1991-10-17 Yale University Introduction d'acide nucleique dans des cellules d'origine animale
WO1991016024A1 (fr) * 1990-04-19 1991-10-31 Vical, Inc. Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives
WO1991017773A2 (fr) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh Nouveaux conjugues de proteines et de polycations
WO1992022635A1 (fr) * 1991-06-05 1992-12-23 University Of Connecticut Apport cible de genes codant des proteines secretoires

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
WO1987002061A1 (fr) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Nouveaux systemes d'administration de medicaments a base de lipoproteines
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1990009786A1 (fr) * 1989-02-24 1990-09-07 City Of Hope Oligomeres heterologues en blocs
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU6909091A (en) * 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
MX9504664A (es) * 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650909A (en) * 1984-11-28 1987-03-17 Yoakum George H Polyethylene glycol (PEG) reagent
EP0388758A1 (fr) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Conjugé protéine-polycation
EP0394111A1 (fr) * 1989-04-17 1990-10-24 Centre National De La Recherche Scientifique (Cnrs) Nouvelles lipopolyamines, leur préparation et leur emploi
WO1991004753A1 (fr) * 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
WO1991015501A1 (fr) * 1990-04-04 1991-10-17 Yale University Introduction d'acide nucleique dans des cellules d'origine animale
WO1991016024A1 (fr) * 1990-04-19 1991-10-31 Vical, Inc. Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives
WO1991017773A2 (fr) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh Nouveaux conjugues de proteines et de polycations
WO1992022635A1 (fr) * 1991-06-05 1992-12-23 University Of Connecticut Apport cible de genes codant des proteines secretoires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARSUKOV L I ET AL: "Affinity chromatography of the phosphatidylcholine exchange protein from bovine liver.", BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 2 NOV 1978, vol. 513, no. 2, 2 November 1978 (1978-11-02), pages 198 - 204, XP009000571, ISSN: 0006-3002 *
COTTEN M ET AL: "TRANSFERRIN-POLYCATION-MEDIATED INTRODUCTION OF DNA INTO HUMAN LEUKEMIC CELLS: STIMULATION BY AGENTS THAT AFFECT THE SURVIVAL OF TRANSFECTED DNA OR MODULATE TRANSFERRING RECEPTOR LEVELS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, 1 June 1990 (1990-06-01), pages 4033 - 4037, XP000619579, ISSN: 0027-8424 *
FELGNER P L ET AL: "LIPOFECTON: A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 84, no. 21, 1 November 1987 (1987-11-01), pages 7413 - 7417, XP000602252, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655468B2 (en) 1995-01-23 2010-02-02 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production

Also Published As

Publication number Publication date
JP2007006899A (ja) 2007-01-18
AU4027893A (en) 1993-11-08
CA2133323C (fr) 2010-10-26
EP0636028A4 (fr) 1998-12-09
AU682308B2 (en) 1997-10-02
ATE260679T1 (de) 2004-03-15
JP2005110696A (ja) 2005-04-28
JP3907662B2 (ja) 2007-04-18
US5977084A (en) 1999-11-02
DE69333434T2 (de) 2005-03-03
DK0636028T3 (da) 2004-07-12
US6300317B1 (en) 2001-10-09
EP0636028B1 (fr) 2004-03-03
WO1993019768A1 (fr) 1993-10-14
JP3688278B2 (ja) 2005-08-24
JP4074658B2 (ja) 2008-04-09
PT636028E (pt) 2004-07-30
US5955365A (en) 1999-09-21
JPH07505639A (ja) 1995-06-22
JP2004000245A (ja) 2004-01-08
CA2133323A1 (fr) 1993-10-14
DE69333434D1 (de) 2004-04-08
ES2221920T3 (es) 2005-01-16
EP1236473A2 (fr) 2002-09-04
JP3950472B2 (ja) 2007-08-01
AU682308C (en) 2006-08-17
EP0636028A1 (fr) 1995-02-01

Similar Documents

Publication Publication Date Title
EP0636028A4 (fr) Systeme de livraison d'un polynucleotide a assemblage autonome.
CA2163364A1 (fr) Systeme d'administration auto-elabore de polynucleotides, renfermant des polycations dendrimeres
EP0643976A3 (fr) Dispositif d'administration cardioplégique.
AU6017994A (en) Language-sensitive collation system
EP0551243A3 (en) Address recognition engine
EP0619501A3 (en) Sonar system.
EP0612929A3 (fr) Dispositif de transmission.
ZA973632B (en) Methods for destroying colliery methane and systems for practicing same.
HUP9903792A3 (en) Percutaneous delivery system
EP0640832A3 (fr) Système à base d'immunocapteur électrochimique.
EP0638887A3 (fr) Système embarqué de navigation pour véhicules.
DE69631808D1 (de) Konferenzsystem, Endgerätkommunikationsverfahren und Speichereinheit zur Speicherung des Verfahrens
NO20001516D0 (no) Kombinert adresse- og postetikett, samt system for å fremstille det samme
EP0604148A3 (fr) Système à adresser et à affranchir.
EP0645720A3 (fr) Système de support pour la création de dictionnaires.
ZA968833B (en) Gelled near tricritical point compositions.
EP0637525A3 (fr) Procédé pour éviter les collisions entre véhicules.
AU6205490A (en) Fungal expression system
WO1999012945A3 (fr) Derives de glycosylamine hydrophobes, compositions a base de ces derives et procedes d'utilisation
EP0624258A4 (fr) Systeme de microscopie.
IT1284632B1 (it) Perfezionamento nelle strutture di abitacolo per autoveicoli.
EP0651591A3 (fr) Système d'électrodes.
EP0644438A3 (fr) Système radar.
EP0657593A3 (fr) Système de connexion.
AU3698593A (en) ACC 300 accumulator system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 636028

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAENSLER, JEAN

Inventor name: SZOKA, FRANCIS C., JR.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAENSLER, JEAN, AVENTIS PASTEUR SA

Inventor name: SZOKA, FRANCIS C., JR.

17P Request for examination filed

Effective date: 20030710

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030904

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051019